asunaprevir

Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.

In the Vinony graph

Vinony's link graph records 102 inbound references to asunaprevir, and connects out to phase of clinical research, Russia and Japan.

It is catalogued under topics including Acylsulfonamides, Carbamates and Chloroarenes.

Vinony links it to 9 Wikipedia language editions.

Chemical data

Formula: C35H46ClN5O9S
Molecular weight: 748.3 g/mol
IUPAC name: tert-butyl N-[(2S)-1-[(2S,4R)-4-(7-chloro-4-methoxyisoquinolin-1-yl)oxy-2-[[(1R,2S)-1-(cyclopropylsulfonylcarbamoyl)-2-ethenylcyclopropyl]carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
SMILES: CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
InChIKey: XRWSZZJLZRKHHD-WVWIJVSJSA-N
XLogP: 4.9
Polar surface area: 191 Å²
H-bond donors: 3
H-bond acceptors: 10
Formal charge: 0

via PubChem

Drug data · ChEMBL

Max clinical phase: Approved
Molecule type: Small molecule
First approval: 2014
Admin. routes: oral
Indications: hepatitis C virus infection, chronic hepatitis C virus infection, infection, viral disease

via ChEMBL · EBI

Research

465 papers

Asunaprevir.Australian prescriber · 2016
Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.Clinical pharmacokinetics · 2015
Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.Therapeutics and clinical risk management · 2014
Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.Expert review of anti-infective therapy · 2015
Asunaprevir for hepatitis C: a safety evaluation.Expert opinion on drug safety · 2015

via PubMed

Wikidata facts

Mass: 747.27

Show 4 more facts

subject has role: protease inhibitor
chemical formula: C₃₅H₄₆ClN₅O₉S
isomeric SMILES: CC(C)(C)[C@@H](C(=O)N1C[C@@H](C[C@H]1C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
canonical SMILES: CC(C)(C)C(C(=O)N1CC(CC1C(=O)NC2(CC2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C

Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

1 sections

Contents

References

Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3. Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.

Excerpted from Wikipedia’s “asunaprevir” article, available under the CC BY-SA 4.0 licence.